2017 Parkinson Study Group Symposium and Training

2017年帕金森研究组研讨会及培训

• 批准号: 9398499
• 负责人: MICHAEL A SCHWARZSCHILD
• 金额: $ 2.5万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-07-01 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9398499
• 关键词: Advocate; Alzheimer' s Disease; Ataxia; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Development; Disease; Dystonia; Education; Educational Activities; Educational workshop; Ensure; Etiology; Fostering; Foundations; Future; Gilles de la Tourette syndrome; Goals; Huntington Disease; Immunotherapeutic agent; Immunotherapy; Investments; Knowledge; Learning; Mentors; Modification; Movement Disorders; Neurobiology; Neurodegenerative Disorders; Neurology; Parkinson Disease; Pathogenesis; Patient Care; Patients; Peer Review; Pharmacology; Program Reviews; Research; Research Activity; Research Methodology; Research Personnel; Research Project Grants; Research Proposals; Scientist; Therapeutic; Training; Training and Education; Translational Research; Tremor; career; career development; design; drug development; experience; genetic epidemiology; improved; insight; meetings; mobile computing; nervous system disorder; neuroimaging; novel; novel therapeutics; patient oriented; posters; programs; research study; skills; symposium; tool

Abstract The proposed conference project, centered on the annual clinical research symposium of the Parkinson Study Group (PSG) and associated annual meeting activities, will foster the education and training of early stage investigators to ensure that the highest quality translational and clinical research continues to be conducted toward improved therapy for Parkinson's and related neurological disease. This project goal will be achieved through two specific aims (SAs). In SA #1, the PSG will present the “31st Annual Symposium on the Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders” in collaboration with the Huntington Study Group (HSG), Dystonia Study Group (DSG), Tourette Syndrome Study Group (TSSG), Cooperative Ataxia Group (CAG), and Tremor Research Group (TRG) on Monday, September 17, 2017 in Fort Myers, FL. The peer-reviewed program includes both platform and poster presentations in a live format with audience participation. The symposium will focus on the emergence of immuno-therapy as a promising strategy for disease modification in Parkinson's and other neurodegenerative diseases, with keynote talks conveying complementary neurobiological, drug development, regulatory and patient perspectives. SA #2 is designed to provide early-stage clinical investigators with movement disorders training a multi-faceted practical orientation to PD clinical research. The selected junior investigators will participate in several novel and interactive, educational research activities in addition to the symposium, including a) direct exchange with experienced patient advocates of the Parkinson's Disease Foundation's PAIR (Parkinson's Advocates in Research) program to learn how patient input can benefit their research, and b) the PSG Mentoring Committee's junior investigator workshop on novel research methodologies. Junior investigators completing participation in the project will be substantially better prepared and motivated to pursue careers and studies in clinical neurology.

摘要 拟议的会议项目，以美国医学会的年度临床研究研讨会为中心 帕金森研究小组(PSG)和相关的年度会议活动将促进 对早期调查人员进行教育和培训，以确保最高质量的翻译 继续进行临床研究，以改进帕金森氏症和 相关的神经疾病。该项目目标将通过两个具体目标(SA)来实现。 在SA#1中，PSG将提交第31届病因学、发病机制和 帕金森氏症及其他运动障碍的治疗“ 亨廷顿研究小组(HSG)、肌张力障碍研究小组(DSG)、多发性抽动症研究小组 (TSSG)、合作共济失调组织(CAG)和震颤研究小组(TRG)周一， 2017年9月17日，佛罗里达州迈尔斯堡。同行评审计划包括平台和 有观众参与的现场形式的海报演示。研讨会的重点将是 免疫疗法的出现是一种有希望的疾病改良策略 帕金森和其他神经退行性疾病，主旨演讲传达 互补的神经生物学、药物开发、监管和患者视角。SA#2 旨在为早期临床研究人员提供运动障碍培训和 多方位开展帕金森病临床研究。选定的初级调查员将 参加一些新颖和互动的教育研究活动，除了 研讨会，包括与帕金森氏症有经验的患者代言人直接交流 疾病基金会的Pair(帕金森研究倡导者)计划了解患者 投入可以使他们的研究受益，以及b)PSG指导委员会的初级调查员 创新研究方法研讨会。初级调查人员完成参与 项目将有更好的准备和动力来追求职业生涯和学习 临床神经学。